Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk

March 8, 2024

Annals of Surgical Oncology 2024 February 19 [Link] Varun V Bansal, Owen Mitchell, Celyn Bregio, Hunter D D Witmer, Ankit Dhiman, Frederick A Godley 4th, Cecilia Ong, Yaniv Berger, Biren Reddy, Jane E Churpek, Michael W Drazer, Oliver S Eng, Hedy L Kindler, Kiran K Turaga Abstract Introduction: Venous thromboembolism (VTE) is a common complication…

Read More

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

March 6, 2024

JAMA Oncology 2024 February 15 [Link] Peter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Olga Olevsky, Federica Grosso, Diego Cortinovis, Meenali Chitnis, Amy Roy, David Gilligan, Hedy Kindler, Dionysis Papadatos-Pastos, Giovanni L Ceresoli, Aaron S Mansfield, Anne Tsao, Kenneth J O’Byrne, Anna K Nowak, Jeremy Steele, Michael Sheaff, Chiung-Fang Shiu, Chih-Ling…

Read More

Is extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?

February 29, 2024

Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…

Read More

BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma

February 28, 2024

Journal of Cancer Research and Clinical Oncology 2024 January 27 [Link] Tuna Han Yuce, Guntulu Ak, Selma Metintas, Emine Dundar, Oluf Dimitri Roe, Vasiliki Panou, Muzaffer Metintas Abstract Purpose: There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic…

Read More

Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream

February 23, 2024

Frontiers in Immunology 2024 January 8 [Link] Luana Calabrò, Giuseppe Bronte, Federica Grosso, Luigi Cerbone, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Lucio Crinò, Michele Maio Abstract Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the…

Read More

Impact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma

February 22, 2024

Journal of Thoracic Disease 2023 December 30 [Link] Douglas Z Liou, Yoyo Wang, Prasha Bhandari, Joseph B Shrager, Natalie S Lui, Leah M Backhus, Mark F Berry Abstract Background: Modern treatment guidelines recommend multimodal therapy with at least chemotherapy and surgery for patients with potentially resectable epithelioid mesothelioma. This study evaluated guideline compliance for patients…

Read More

The knockdown of stathmin with si-RNA inhibits invasion of mesothelioma

February 20, 2024

Tissue and Cell 2024 January 5 [Link] Asude Aksoy, Asuman Varoglu, Ebru Etem Onalan, Ahmet Tektemur, Gokhan Artas, Mustafa Koc, Muharrem Cakmak, Siyami Aydin, Murat Kilic, Mustafa Ulas Abstract Background: To investigate the mechanism of action of stathmin1 (STMN1) in mesothelioma (MSM) and whether it has any role in its treatment. Methods: STMN1 expression was…

Read More

Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural cisplatin perfusion for malignant pleural mesothelioma

February 14, 2024

JTCVS Open 2023 September 14 [Link] Kenichi Okubo, Hironori Ishibashi, Ryo Wakejima, Shunichi Baba, Ayaka Asakawa, Hiroshi Seshima Abstract Objective: To evaluate the efficacy of multimodality treatment including extended pleurectomy/decortication (P/D) and hyperthermic intraoperative chemotherapy (HIOC) with cisplatin for malignant pleural mesothelioma (MPM), we investigated the pharmacokinetics of platinum, adverse events after HIOC, and survival…

Read More

PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma

February 1, 2024

Frontiers in Oncology 2023 December 4 [Link] Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F Cardona, Cittim B Palomares-Palomares, Oscar Arrieta Abstract Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant…

Read More